GlassScriptPhysician profile
Tarah Brennan
NPI 1275009524
$3,429.71
in general payments reported to CMS, 2019-2025
27 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,140 · 2022: $1,350 · 2023: $461 · 2024: $376 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.53 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $529.20 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $308.33 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bausch Health US, LLC | $229.82 | 2021-2024 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $220.83 | 2021-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $182.21 | 2022-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $169.26 | 2021-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $142.14 | 2021-2025 | Fanapt, Hetlioz |
| Eisai INC. | $136.36 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $135.32 | 2021-2024 | Rexulti |
| Lundbeck LLC | $115.87 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $91.72 | 2021-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $83.56 | 2021-2022 | |
| Indivior INC. | $82.75 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $67.98 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $60.48 | 2021-2022 | |
| Axsome Therapeutics, INC. | $51.81 | 2023-2024 | Auvelity, Sunosi |
| Noven Therapeutics, LLC | $42.91 | 2022 | |
| Merck Sharp & Dohme LLC | $37.79 | 2021-2022 | |
| Almatica Pharma LLC | $36.34 | 2022-2023 | Loreev Xr |
| Biogen, INC. | $32.55 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.75 | 2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $17.50 | 2021 | |
| Novo Nordisk INC | $16.88 | 2023 | Wegovy |
| Sun Pharmaceutical Industries INC. | $14.60 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.39 | 2022 | |
| Acadia Pharmaceuticals INC | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarah Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.